Literature DB >> 18609031

The validity of schizophrenia diagnosis in the Finnish Hospital Discharge Register: findings from a 10-year birth cohort sample.

Johanna Pihlajamaa1, Jaana Suvisaari, Markus Henriksson, Hannele Heilä, Elisa Karjalainen, Johanna Koskela, Mary Cannon, Jouko Lönnqvist.   

Abstract

The purpose of this study was to investigate the diagnostic validity of schizophrenia in the Finnish Hospital Discharge Register (FHDR) with a large, epidemiologically representative sample using a multidiagnostic approach (DSM-III-R, DSM-IV, ICD-10), and to find additional criteria that could be used to improve the validity of schizophrenia diagnosis in future register-based research that utilizes the FHDR. The study population consisted of all individuals (n=877) who were born in Helsinki, Finland, between 1 January 1951 and 31 December 1960, and who had had at least one diagnosis of schizophrenia, schizophreniform disorder or schizoaffective disorder in the FHDR. All their available hospital case notes were collected. The total number of subjects for whom case notes were obtained was 806. We used the OPCRIT system (version 3.4) to produce diagnoses according to ICD-10, DSM-III-R and DSM-IV criteria based on the information extracted from the hospital case notes. We examined the distribution of the DSM-III-R, DSM-IV and ICD-10 diagnoses generated by the OPCRIT and calculated the proportion of individuals who received the same diagnosis in the FHDR and in the OPCRIT assessment. The proportion of subjects who received a core schizophrenia spectrum diagnosis (schizophrenia, schizoaffective disorder or schizophreniform disorder) in both the FHDR and OPCRIT assessment varied between 75% (DSM-III-R criteria) and 78% (ICD-10 criteria). Of the subjects with a narrow schizophrenia diagnosis in the FHDR, between 74% (DSM-IV) and 78% (ICD-10) received a diagnosis of schizophrenia in the reassessment depending on the diagnostic criteria applied. Eighty per cent of those who had received a core schizophrenia spectrum FHDR diagnosis after 1982 (vs. 56% of those who had received their last schizophrenia diagnosis in 1982 or before) received a DSM-IV diagnosis of core schizophrenia spectrum disorder. Of the 58 subjects in the sample who had been given at various times diagnoses of both core schizophrenia diagnosis and bipolar I diagnosis in FHDR, 43% received a core schizophrenia spectrum diagnosis according to DSM-IV criteria. The validity of the FHDR schizophrenia diagnosis is acceptable for large-scale register studies and comparable with that of other Nordic registers. Diagnostic validity can be further improved by selecting subjects who have core schizophrenia spectrum disorder as the latest diagnosis, by omitting cases diagnosed before 1982, and by excluding cases with a register diagnoses of both a core schizophrenia spectrum and bipolar I disorder.

Entities:  

Mesh:

Year:  2008        PMID: 18609031     DOI: 10.1080/08039480801983596

Source DB:  PubMed          Journal:  Nord J Psychiatry        ISSN: 0803-9488            Impact factor:   2.202


  31 in total

1.  Advanced paternal age and parental history of schizophrenia.

Authors:  Brian Miller; Jaana Suvisaari; Jouko Miettunen; Marjo-Riitta Järvelin; Jari Haukka; Antti Tanskanen; Jouko Lönnqvist; Matti Isohanni; Brian Kirkpatrick
Journal:  Schizophr Res       Date:  2011-09-19       Impact factor: 4.939

Review 2.  First rank symptoms for schizophrenia.

Authors:  Karla Soares-Weiser; Nicola Maayan; Hanna Bergman; Clare Davenport; Amanda J Kirkham; Sarah Grabowski; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2015-01-25

3.  Who are the restrained and secluded patients: a 15-year nationwide study.

Authors:  Alice Keski-Valkama; Eila Sailas; Markku Eronen; Anna-Maija Koivisto; Jouko Lönnqvist; Riittakerttu Kaltiala-Heino
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-10-21       Impact factor: 4.328

4.  Demographic Characteristics and Psychiatric Comorbidity of Children and Adolescents Diagnosed with ADHD in Specialized Healthcare.

Authors:  Petteri Joelsson; Roshan Chudal; David Gyllenberg; Anna-Kaisa Kesti; Susanna Hinkka-Yli-Salomäki; Juha-Pekka Virtanen; Jukka Huttunen; Terja Ristkari; Kai Parkkola; Mika Gissler; Andre Sourander
Journal:  Child Psychiatry Hum Dev       Date:  2016-08

5.  Substance use disorders in schizophrenia, bipolar disorder, and depressive illness: a registry-based study.

Authors:  Ragnar Nesvåg; Gun Peggy Knudsen; Inger Johanne Bakken; Anne Høye; Eivind Ystrom; Pål Surén; Anne Reneflot; Camilla Stoltenberg; Ted Reichborn-Kjennerud
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2015-02-14       Impact factor: 4.328

6.  Validation study of the early onset schizophrenia diagnosis in the Danish Psychiatric Central Research Register.

Authors:  Ditte Lammers Vernal; Anne Dorte Stenstrøm; Nina Staal; Anne Marie Raabjerg Christensen; Christine Ebbesen; Anne Katrine Pagsberg; Christoph U Correll; René Ernst Nielsen; Marlene Briciet Lauritsen
Journal:  Eur Child Adolesc Psychiatry       Date:  2018-01-03       Impact factor: 4.785

Review 7.  Diagnosis of schizophrenia: consistency across information sources and stability of the condition.

Authors:  Philip D Harvey; Robert K Heaton; William T Carpenter; Michael F Green; James M Gold; Michael Schoenbaum
Journal:  Schizophr Res       Date:  2012-04-13       Impact factor: 4.939

8.  Impact of Cannabis Use on the Development of Psychotic Disorders.

Authors:  Samuel T Wilkinson; Rajiv Radhakrishnan; Deepak Cyril D'Souza
Journal:  Curr Addict Rep       Date:  2014-06-01

9.  Involuntary commitment and detainment in adolescent psychiatric inpatient care.

Authors:  Riittakerttu Kaltiala-Heino
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-08-19       Impact factor: 4.328

10.  Obstetric complications as risk factors for schizophrenia spectrum psychoses in offspring of mothers with psychotic disorder.

Authors:  Jaana M Suvisaari; Virpi Taxell-Lassas; Maiju Pankakoski; Jari K Haukka; Jouko K Lönnqvist; Laura T Häkkinen
Journal:  Schizophr Bull       Date:  2012-09-20       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.